Oral Presentation
Therapeutic trials in lung cancer
08:30
Introduction: The role of the respiratory physician in therapeutic trials in lung cancer
A. Rittmeyer(Immenhausen, Germany)
COI
1
OA6010
08:45
Co-expression of S100A14 and S100A16 is a predictive marker for platinum-based adjuvant chemotherapy in resected lung adenocarcinomas
K. Katono(Sagamihara (Kanagawa prefecture), Japan)
COI
2
09:00
24h-blood profile gene expression biomarkers of the response to bevacizumab-erlotinib (BE) in advanced non-squamous non-small cell lung cancer (NSCLC)
F. Baty(St. Gallen, Switzerland)
COI
3
09:15
Gefitinib versus erlotinib as first-line treatment in EGFR mutant advanced lung adenocarcinoma
C. Chai(Petaling Jaya (Selangor), Malaysia)
COI
4
09:30
Afatinib (A) vs gefitinib (G) as first-line treatment (tx) for patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: LUX-Lung 7
V. Hirsh(Montréal (QC), Canada)
COI
5
09:45
A case series of eight patients treated with alectinib including a case of interstitial lung disease
Y. Sakata(Kumamoto, Japan)
COI
6
10:00
A phase II trial of lipoplatin and gemcitabine in patients with NSCLC previously treated with platinum-based chemotherapy
M. Froudarakis(Alexandroupolis, Greece)
COI
7
10:15
A phase III randomised trial testing chemotherapy in extensive small-cell lung cancer (SCLC)
J. Sculier(Bruxelles, Belgium)
COI
8
. . .
